|Articles|October 7, 2014
Novotech Expands Services to China
Novotech, Australia?s largest clinical CRO with offices throughout Asia, announced today the expansion of services to China with a Novotech office in Shanghai, a wholly owned entity with local staff. Shanghai is the ninth Novotech office in Asia.
Advertisement
Novotech, an Australian CRO with offices throughout Asia,
China with a Novotech office in Shanghai, a wholly owned entity with local staff. Shanghai is the ninth Novotech office in Asia. Novotech Asia COO, Dr. John Moller said China is now the largest clinical trial destination in Asia, and the 5th largest in the world.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
2
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
5